Sanofi and Amgen Inc. are turning to heavyweight appellate talent as they prepare to duke it out over an injunction that orders Sanofi’s Praluent cholesterol medicine off the market.
Kirkland & Ellis partner Paul Clement filed Sanofi’s motion for an emergency stay Jan. 13 evening at the U.S. Court of Appeals for the Federal Circuit. Failing to grant it, he wrote, would deprive thousands of patients “life-saving” medicine, throw Sanofi employees out of work and renegotiate contracts with insurers and pharmacy benefit managers. “The district court recognized that this extraordinary remedy was contrary to the public interest, but ordered it anyway,” he wrote.
